$ISRG

LOEB GARY sold $152K of ISRG

LOEB GARY (EVP & Chief Legal and Complian) sold 400 shares of INTUITIVE SURGICAL INC (ISRG) at $379.00 ($0.15M total) on 2026-08-10 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · LOEB GARY
Published Aug 10, 2026, 9:55 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 10, 2026, 9:56 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ISRG
Neutral
high confidence
Mentioned
$ISRG
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ISRGNeutralLow
01

Why it matters

The newest fact is the specific sale: 400 shares at $379 on 2026-08-10, with holdings after transaction of 5,320 shares, under a pre-arranged 10b5-1 plan.

02

Market read

Traders may note insider selling, but the 10b5-1 structure generally makes this more of a compliance disclosure than a fundamental catalyst.

03

What to watch

The filing does not indicate intent beyond the plan, and the share count and dollar value are not described as unusually large relative to typical insider activity, limiting tradable inference.

Relevance 3/10Novelty 3/10Timing: filed on 2026-08-10, after-hours/late session disclosure

Background

The article is a SEC Form 4 insider transaction disclosure for Intuitive Surgical (ISRG).

Company-level read

Ticker impact

$ISRGNeutralHigh confidence
Context

Form 4 shows Loeb Gary, ISRG EVP and Chief Legal and Compliance, sold 400 shares at $379 on 2026-08-10 under a 10b5-1 plan.

Expected impact

Low likelihood of a sustained price move driven by this filing alone.

Evidence & confidence

The disclosure is an insider sale (not a buy), but it is explicitly tied to a pre-arranged 10b5-1 plan, which typically reduces interpretive value versus discretionary selling.

Market effects

No clear sector read-through; this is company-specific insider transaction data.

None indicated.

None indicated.

Counterpoint

Even with a 10b5-1 plan, repeated insider selling can coincide with executives de-risking ahead of known personal liquidity needs, which some traders may still treat as a mild negative sentiment input.

Key entities

  • ISRG

    Intuitive Surgical, the company whose insider transaction is disclosed.

  • LOEB GARY

    EVP and Chief Legal and Compliance officer who executed the sale.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ISRGHighAI 8/10

Intuitive receives CE mark for transvaginal use of da Vinci SP system

Intuitive Surgical (ISRG) received CE mark approval for its da Vinci SP system for transvaginal gynecological procedures in Europe, expanding its use in women's health. The system, already approved for other surgeries, allows single-incision operations, potentially improving recovery and outcomes. It is also approved in the US, Japan, and Korea.

$ISRGHigh

Intuitive announces expanded indication for da Vinci SP in Europe

Intuitive (ISRG) received CE mark approval for transvaginal gynecologic procedures using the da Vinci SP system in Europe, expanding its applications. The approval allows for less invasive options and potentially better recovery experiences. The system is already approved in the US, Japan, and Korea for various procedures.

$IARTMedAI 8/10

Q2 Earnings Outperformers: Integra LifeSciences (NASDAQ:IART) And The Rest Of The Surgical Equipment & Consumables - Specialty Stocks

Integra LifeSciences (IART) reported flat Q2 revenue of $418.8M, meeting expectations. Teleflex (TFX) saw 28.9% revenue growth, beating estimates. LeMaitre (LMAT) missed expectations with 9.6% growth. Intuitive Surgical (ISRG) reported 18.5% growth, beating estimates. All stocks declined post-earnings, with IART down 17.7%, TFX flat, LMAT down 24.9%, and ISRG down 12.3%.

$ISRGMed

ISRG Stock Trading at its Cheapest in 10 Years: Should You Buy Now?

Intuitive Surgical (ISRG) trades at its lowest valuation in a decade, with a forward P/E of 30.26x, below its 10-year median. Despite a 40% decline, Q2 2026 revenue grew 19% to $2.89B, and EPS rose 28%. Management maintained 2026 da Vinci procedure growth forecast at 13.5-15.5%, citing international growth but noting U.S. and China uncertainties. ISRG's product pipeline includes da Vinci 5 and Ion systems, with innovations like SP procedures up 61%. Shares lag industry and sector, down 15% in 3